发明名称 Neuregulin Allosteric Anti-HER3 Antibody
摘要 The present disclosure relates to neuregulin (NRG)-non competitive allosteric anti-human-HER3 antibodies and uses thereof in diagnostic and therapeutic methods.
申请公布号 US2016319033(A1) 申请公布日期 2016.11.03
申请号 US201315035129 申请日期 2013.11.07
申请人 INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ;UNIVERSITE DE MONTPELLIER ;INSTITUT RÉGIONAL DU CANCER DE MONTPELLIER 发明人 Chardes Thierry;Gaborit Nadege;Larbouret Christel;Pelegrin Andre
分类号 C07K16/32;G01N33/574 主分类号 C07K16/32
代理机构 代理人
主权项 1. An neuregulin noncompetitive allosteric anti-human-HER3 antibody comprising a heavy chain wherein a variable domain comprises: a H-CDR1 having at least 90% or 95% identity with sequence set forth as SEQ ID NO: 2, a H-CDR2 having at least 90% or 95% identity with sequence set forth as SEQ ID NO: 3, a H-CDR3 having at least 90% or 95% identity with sequence set forth as SEQ ID NO: 4, a L-CDR1 having at least 90% or 95% identity with sequence set forth as SEQ ID NO: 6, a L-CDR2 having at least 90% or 95% identity with sequence set forth as SEQ ID NO: 7, a L-CDR3 having at least 90% or 95% identity with sequence set forth as SEQ ID NO: 8, wherein the neuregulin noncompetitive allosteric anti-human-HER3 antibody specifically binds to HER3 with substantially the same affinity as an antibody comprising a heavy chain wherein the variable domain comprises SEQ ID NO: 2 for H-CDR1, SEQ ID NO: 3 for H-CDR2 and SEQ ID NO: 4 for H-CDR3 and a light chain wherein the variable domain comprises SEQ ID NO: 6 for L-CDR1, SEQ ID NO: 7 for L-CDR2 and SEQ ID NO: 8 for L-CDR3.
地址 Paris FR